Table 5 Potential improvement in adequacy of empiric coverage for catheter-related bloodstream infection at 12 h, 24 h, and 48 h using WISCA empiric regimens
WISCA empiric regimens | Percentage of CRBSI with documented adequate coverage by this regimen (n = 56) | Excess percentage of adequate coverage compared to retrospective cohort | ||
|---|---|---|---|---|
12 h | 24 h | 48 h | ||
Monotherapy | ||||
Ciprofloxacin | 28 (50%) | +20% | +2% | -21% |
Tobramycin | 20 (36%) | +6% | -12% | -35% |
Ceftriaxone | 18 (32%) | +2% | -16% | -39% |
Ceftazidime | 19 (34%) | +4% | -13% | -37% |
Pip.-tazo. | 29 (52%) | +22% | +4% | -19% |
Ertapenem | 23 (41%) | +11% | -7% | -30% |
Meropenem | 30 (54%) | +24% | +6% | -17% |
Cloxacillin | 1 (2%) | -28% | -47% | -69% |
Vancomycin | 31 (55%) | +25% | +7% | -16% |
Linezolid | 32 (57%) | +27% | +9% | -14% |
Dual-combination therapy | ||||
Meropenem + Vancomycin* | 53 (95%) | +65% | +47% | +24% |
Ertapenem + Vancomycin | 50 (89%) | +59% | +42% | +18% |
Pip.-Tazo. + Vancomycin* | 52 (93%) | +63% | +45% | +22% |
Ceftazidime + Vancomycin* | 52 (93%) | +63% | +45% | +22% |
Ceftriaxone + Vancomycin | 49 (88%) | +58% | +40% | +17% |
Ciprofloxacin + Vancomycin | 52 (93%) | +63% | +45% | +22% |
Tobramycin + Vancomycin | 50 (89%) | +59% | +41% | +18% |
Ciprofloxacin + Cloxacillin | 35 (63%) | +33% | +15% | -8% |
Tobramycin + Cloxacillin | 23 (41%) | +11% | -7% | -30% |
Meropenem + Tobramycin | 32 (57%) | +27% | +9% | -14% |
Ertapenem + Tobramycin | 33 (59%) | +29% | +11% | -12% |
Pip.-Tazo. + Tobramycin | 32 (57%) | +27% | +9% | -14% |
Ceftazidime + Tobramycin | 23 (41%) | +11% | -7% | -30% |
Ceftriaxone + Tobramycin | 23 (41%) | +11% | -7% | -30% |
Meropenem + Ciprofloxacin | 42 (75%) | +45% | +27% | +4% |
Ertapenem + Ciprofloxacin | 43 (77%) | +47% | +29% | +6% |
Pip.-Tazo. + Ciprofloxacin | 42 (75%) | +45% | +27% | +4% |
Ceftazidime + Ciprofloxacin | 37 (66%) | +36% | +18% | -5% |
Ceftriaxone + Ciprofloxacin | 37 (66%) | +36% | +18% | -5% |
Ciprofloxacin + Tobramycin | 36 (64%) | +34% | +16% | -7% |